HBOT for Lyme Disease: What the Evidence Actually Shows

The short answer: No randomized controlled trial has ever tested HBOT for Lyme disease, nothing is registered on ClinicalTrials.gov, and the entire peer-reviewed literature is one single-patient case report (Huang 2014). The “85% improvement” study every clinic cites (Fife, Texas A&M, 1997) was never published in a peer-reviewed journal. HBOT is not FDA-cleared for Lyme, not a UHMS indication, and not covered by Medicare, so every Lyme use is off-label and cash-pay.

That paragraph is uncomfortable to write as a chamber manufacturer, and it is the only honest way to open this topic. Lyme disease is real, the suffering that can persist after treatment is real and documented, and the people searching this question are often years into an illness that medicine has not fully solved. They deserve the whole record rather than the highlight reel, so this guide traces every major claim to its source: what exists, what was never published, and what the standard-care evidence actually says. The full, expanded analysis lives on our pillar page, Lyme disease and hyperbaric oxygen therapy; this article is the condensed version.

Disclosure: Superhuman Chambers manufactures and sells hard-shell hyperbaric chambers. This article summarizes published research and is not medical advice. Antibiotics are the evidence-based treatment for Lyme disease; never delay, skip, or replace them with chamber sessions. Anyone with a new tick bite, spreading rash, facial droop, palpitations, or new joint swelling should see a physician, not a wellness studio.

The empty bucket, itemized

Before any claim can be graded, the baseline has to be stated plainly, because most Lyme-HBOT marketing depends on the reader never checking it. We verified the emptiness three separate ways, and each is worth knowing on its own.

• PubMed: the only peer-reviewed hyperbaric-Lyme publication that exists is a 2014 case report. There is no Fife Lyme paper, no case series, no trial.
• ClinicalTrials.gov: a search for Lyme disease plus hyperbaric oxygen returns zero registered studies, recruiting or otherwise. There is no “emerging research” a clinic can honestly point to; when one tells you research is ongoing, ask for the registration number.
• The textbook chapter: the Fife group’s own summary of the Lyme work appears as a chapter in the Textbook of Hyperbaric Medicine (Springer, 2017), written by his colleagues, not as a journal article. A book chapter by the team that ran the study is not peer review of that study.

Huang 2014: the one case report, in full context

The single publication is worth reading on its own terms, because it is genuinely intriguing and genuinely limited at the same time. Huang and colleagues in Taiwan reported a man with serology-positive Lyme disease whose joint pain, numbness, sleep disorder, and cognitive symptoms persisted through roughly four years of sequential antibiotics. After excluding other causes, they gave him 30 sessions of HBOT at 2.5 ATA, 90 minutes each, and reported his symptoms resolving in stages across the course.

That is a real patient and a real report. It is also one patient, with no control group, no sham, no blinding, no microbiological endpoint (nothing shows the infection, if still present, was eradicated), and no stated follow-up. Symptoms in this population fluctuate on their own, so improvement over two months cannot be attributed to the chamber without a comparison arm. The word “effective” in the title is a case-report word, not an evidence grade.

The 85% claim, traced

The number that built this market deserves its own audit, because you will meet it on nearly every clinic page. Around 1997, William Fife’s group at the Texas A&M Hyperbaric Laboratory treated a series of Lyme patients with HBOT. The work was never published in a peer-reviewed journal, no dataset survives for public audit, and the tellings disagree with each other: one clinic PDF says 85% of 66 treated patients improved, while other pages describe 91 enrolled patients and 1,995 treatments. Numbers that cannot be checked against a paper cannot carry the weight placed on them. No randomization, no control group, no pre-registered endpoints: this is not a scandal, it is simply not evidence. When any provider quotes you a percentage for Lyme and HBOT, the one question that matters is: published where?

”Oxygen kills the bacteria,” graded

Every Lyme-HBOT page leads with the same mechanism pitch: Borrelia burgdorferi, the Lyme spirochete, is microaerophilic (it prefers low oxygen), so pressurized oxygen must create an environment it cannot survive. The premise is true. The conclusion has never been demonstrated, and the one directly relevant study cuts the other way.

Austin (1993) kept an infective Borrelia burgdorferi strain alive in culture through 20 passages at 4% oxygen and through 15 passages even in ambient air (about 21% oxygen) before losing infectivity as a culturing artifact. The organism prefers low oxygen but demonstrably tolerates ordinary oxygenated tissue conditions for weeks. No study, in vitro, in an animal model, or in a human, shows pressure oxygen killing Borrelia. The mechanism is not “preliminary”; it is asserted.

There is also a quieter problem with the premise: the symptoms that persist after Lyme treatment may not be driven by live bacteria at all. That is the leading interpretation of why months of extra antibiotics matched placebo in the NIH-funded retreatment trials (below). A therapy sold as an antibiotic you sit inside may be solving a problem that is no longer the problem.

What standard care actually says

The Lyme literature on the conventional side is strong, and it belongs in any honest HBOT discussion, because it defines both the treatment and the gap the chamber market sells into.

Two things are true at once, and honest pages hold both: the suffering measured in the Klempner trials was severe, and the desperation that suffering produces is a market. What the terminology fight (PTLDS versus “chronic Lyme”) does not change is the HBOT question. In every labeled group, the controlled evidence for a chamber is the same empty bucket.

The Herxheimer question

Many Lyme patients are told that feeling worse mid-package is a good sign, a “Herxheimer reaction” proving the bacteria are dying. The reaction is real, and the literature on it is specific. Within 24 hours of starting antibiotics for a spirochetal infection, some patients get shaking chills, a fever spike, and a symptom flare that resolves within hours, driven by bacterial proteins and the immune response to organisms actually being killed. In Lyme trials, it occurred in roughly 5 to 30 percent of patients, depending on the antibiotic (Butler 2017).

Every documented case shares one feature: an antimicrobial drug doing measurable killing. There is no published evidence that HBOT produces a Herxheimer reaction, because there is no published evidence that HBOT kills Borrelia. A mid-package flare has mundane explanations that need no dying bacteria: ear barotrauma, claustrophobia, the fatigue of daily sessions, and the natural fluctuation of post-treatment symptoms. “It gets worse before it gets better” is unfalsifiable sales armor; a provider who reaches for it should be able to show you the paper, and there is not one.

The market, documented in peer-reviewed journals

The targeting of this audience is not an allegation; it is measured. Lantos and colleagues (2015), writing in Clinical Infectious Diseases, cataloged more than 30 unorthodox therapies marketed specifically to Lyme patients, oxygen and reactive oxygen therapy among them, and found the literature “did not substantiate efficacy or, in most cases, any rationale” for them. Vox and colleagues (2018), in JAMA, counted 1,059 crowdfunding campaigns seeking $27.2 million for five scientifically unsupported treatments, including long-term antibiotics for “chronic Lyme disease” and HBOT for brain injury.

The sharpest data point comes from inside the community itself. Daniel Cameron, a physician with three decades treating Lyme and a past president of ILADS, the “Lyme-literate” professional society, reviewed HBOT for his patients and concluded that no large controlled trials have demonstrated sustained benefit, and he does not routinely recommend it. When even the clinicians most open to unconventional Lyme care will not endorse the chamber, the sellers quoting Lyme “studies” are out beyond both medical establishments.

The equipment question, honestly

The Lyme community is heavily marketed 1.3 ATA soft home chambers, because daily home sessions fit a chronic illness narrative. The one published case used 2.5 ATA with 100% oxygen in a clinical hard chamber, and soft portable units (cleared by the FDA for acute mountain sickness only) cannot reach that pressure class. Dissolved plasma oxygen scales with pressure, so a mild home session is not a cheaper version of the reported dose; it is a different, completely unstudied one. Our pressure levels explainer covers what each class can and cannot do.

The deeper honesty: no equipment class, at any pressure, has outcome data for Lyme disease. A home chamber converts an unproven per-session expense into an unproven capital expense, and the unknown does not shrink when you own the hardware. Clinical-class work of the kind the one case report used sits in hard-shell, medically supervised territory (our L1 and T2 are built to that engineering class), but that is a hardware statement, not a Lyme claim, and on this topic no manufacturer can honestly make one.

Limitations and open questions

Fairness cuts both directions, and the direction that cuts against our own caution deserves stating as plainly as the rest:

• Absence of trials is not proof of absence of effect. The Huang case is a real report by hospital physicians with no chamber to sell, and PTLDS has no proven treatment. If a proper sham-controlled trial of HBOT as a post-treatment adjunct were run and showed benefit, this article would need rewriting, and we would rewrite it gladly.
• Unproven is not disproven, but the burden of proof sits on the seller. Three decades of marketing this protocol to this community have produced zero controlled data: not one randomized trial, not one registered study, not one replicated case series with a comparison group.
• The standard-care context is the actual safety net. Never delay, skip, or replace antibiotics for documented Lyme disease, and note that untreated Lyme carries real cardiac and neurologic risks that belong to a physician. HBOT itself has a known side-effect profile (ear barotrauma most commonly; rarely oxygen-toxicity seizures) covered in our side effects and contraindications guide.
• Costs are entirely out of pocket. Medicare does not cover HBOT for Lyme and no Lyme-specific pricing is published; clinics commonly sell 40-to-60-session packages. Get the total itemized cost in writing before the first session, and be wary of anything priced to be paid in full up front.

What this means for wellness operators

For operators, the durable position is the accurate one, and with this audience it is also the commercial one, because Lyme patients compare notes in forums for years and remember exactly who told them the truth. Three rules follow directly from the record.

First, there is no number you can honestly quote. Not 85%, not “most patients,” not “emerging research.” You can say that HBOT is not FDA-cleared for Lyme, that no controlled trial exists, and that the peer-reviewed literature is one case report. Anything more confident is invention.

Second, the referral is the product. A client who says “I have had Lyme for six years and nothing works” deserves the full record and a push back toward their physician and the IDSA guideline, never a confirmation of a self-diagnosis or any suggestion of pausing prescribed antibiotics. For the compliance side of condition talk generally, see our FDA-cleared indications guide.

Third, do not sell “herxing.” A mid-package symptom flare is not proof of bacterial die-off; that reaction is documented only with antibiotics. Where HBOT genuinely fits a wellness setting is the recovery and longevity use cases with real literature behind them, and framing those honestly is what builds a defensible program. To talk through positioning, learn more about Superhuman or contact the team.

References

1. Huang CY, Chen YW, Kao TH, et al. Hyperbaric oxygen therapy as an effective adjunctive treatment for chronic Lyme disease (single-patient case report). J Chin Med Assoc. 2014;77(5):269-271. https://pubmed.ncbi.nlm.nih.gov/24726678/
2. Fife CE, Eckert KA. Hyperbaric Oxygen Therapy and Chronic Lyme Disease: The Controversy and the Evidence. In: Textbook of Hyperbaric Medicine, 6th ed. Springer; 2017:171-181. https://link.springer.com/chapter/10.1007/978-3-319-47140-2_15
3. Austin FE. Maintenance of infective Borrelia burgdorferi Sh-2-82 in 4% oxygen, 5% carbon dioxide in vitro. Can J Microbiol. 1993;39(12):1103-1110. https://pubmed.ncbi.nlm.nih.gov/8131108/
4. Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med. 2001;345(2):85-92. https://pubmed.ncbi.nlm.nih.gov/11450676/
5. Lantos PM, Rumbaugh J, Bockenstedt LK, et al. IDSA/AAN/ACR 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clin Infect Dis. 2021;72(1):e1-e48. https://pubmed.ncbi.nlm.nih.gov/33417672/
6. Aucott JN. Posttreatment Lyme disease syndrome. Infect Dis Clin North Am. 2015;29(2):309-323. https://pubmed.ncbi.nlm.nih.gov/25999226/
7. Feder HM Jr, Johnson BJ, O’Connell S, et al. A critical appraisal of “chronic Lyme disease”. N Engl J Med. 2007;357(14):1422-1430. https://pubmed.ncbi.nlm.nih.gov/17914043/
8. Butler T. The Jarisch-Herxheimer Reaction After Antibiotic Treatment of Spirochetal Infections. Am J Trop Med Hyg. 2017;96(1):46-52. https://pmc.ncbi.nlm.nih.gov/articles/PMC5239707/
9. Lantos PM, Shapiro ED, Auwaerter PG, et al. Unorthodox alternative therapies marketed to treat Lyme disease. Clin Infect Dis. 2015;60(12):1776-1782. https://pubmed.ncbi.nlm.nih.gov/25852124/
10. Vox F, Folkers KM, Turi A, Caplan AL. Medical Crowdfunding for Scientifically Unsupported or Potentially Dangerous Treatments. JAMA. 2018;320(16):1705-1706. https://pubmed.ncbi.nlm.nih.gov/30357284/
11. Cameron D. Hyperbaric Oxygen Therapy for Lyme Disease: Does It Help? Physician review by a past ILADS president (opinion, not peer-reviewed), accessed Oct 2026. https://danielcameronmd.com/hyperbaric-oxygen-lyme-disease/
12. ClinicalTrials.gov search: Lyme disease + hyperbaric oxygen, zero registered studies (verified October 2026). https://clinicaltrials.gov/search?cond=Lyme%20Disease&term=hyperbaric